Search
forLearn
1 / 1 resultsResearch
5 / 890 results
research Theoretical Investigation of the Conformational Space of Baicalin
The study found that baicalin has different stable shapes in gas and water, with two shapes better for interacting with positive charges in water.
research Analysis of Hidradenitis Suppurativa-Linked Mutations in Four Genes and the Effects of PSEN1-P242LfsX11 on Cytokine and Chemokine Expression in Macrophages
The document concludes that certain mutations may contribute to the inflammation in hidradenitis suppurativa and suggests that targeting TNFα could be a treatment strategy.
research Structural and Dynamic Insights into Substrate Binding and Catalysis of Human Lipocalin Prostaglandin D Synthase
The research explains how a human enzyme binds and processes its substrate, which could relate to its role in biological functions and hair loss.
research New Challenge to Cancer and Longevity
A group has developed therapies that show promise for treating cancer and various other conditions.
research Structural and Functional Studies of L-PGDS and SMPDL3A Enzymes in Lipid Signaling Family
L-PGDS has specific binding sites for its functions and could help in drug delivery system design.
Community Join
4 / 4 resultscommunity The Real Cause Of Androgenetic Alopecia
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
community Finasteride, dutasteride, and oral min- My experience
User took Fin for 3 years, Dut for 7 months, and oral Min for 2 months without side effects. Fin stopped hair loss for 2 years, Dut maintained hair, and oral Min regrew thinning hair.
community Can't believe I've slept on microneedling for so long.
Microneedling with minoxidil and finasteride greatly improves hair regrowth. Using 0.5mm depth every other day boosts minoxidil absorption without side effects.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.